BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liszewski MK, Leung MK, Schraml B, Goodship TH, Atkinson JP. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol 2007;44:1559-68. [PMID: 17027083 DOI: 10.1016/j.molimm.2006.08.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 de Cordoba SR, Tortajada A, Harris CL, Morgan BP. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology. 2012;217:1034-1046. [PMID: 22964229 DOI: 10.1016/j.imbio.2012.07.021] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 8.9] [Reference Citation Analysis]
2 Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol. 2017;12:25-52. [PMID: 27959629 DOI: 10.1146/annurev-pathol-012615-044145] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
3 Liszewski MK, Bertram P, Leung MK, Hauhart R, Zhang L, Atkinson JP. Smallpox inhibitor of complement enzymes (SPICE): regulation of complement activation on cells and mechanism of its cellular attachment. J Immunol 2008;181:4199-207. [PMID: 18768877 DOI: 10.4049/jimmunol.181.6.4199] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
4 Richards A, Kavanagh D, Atkinson JP. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 2007;96:141-77. [PMID: 17981206 DOI: 10.1016/S0065-2776(07)96004-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
5 Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8:e1001013. [PMID: 21445332 DOI: 10.1371/journal.pmed.1001013] [Cited by in Crossref: 195] [Cited by in F6Publishing: 174] [Article Influence: 17.7] [Reference Citation Analysis]
6 Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13:663-675. [PMID: 23356914 DOI: 10.1111/ajt.12077] [Cited by in Crossref: 153] [Cited by in F6Publishing: 139] [Article Influence: 17.0] [Reference Citation Analysis]
7 Java A, Liszewski MK, Hourcade DE, Zhang F, Atkinson JP. Role of complement receptor 1 (CR1; CD35) on epithelial cells: A model for understanding complement-mediated damage in the kidney. Mol Immunol 2015;67:584-95. [PMID: 26260209 DOI: 10.1016/j.molimm.2015.07.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
8 Naik A, Sharma S, Quigg RJ. Complement regulation in renal disease models. Semin Nephrol 2013;33:575-85. [PMID: 24161042 DOI: 10.1016/j.semnephrol.2013.08.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
9 Thielen AJF, van Baarsen IM, Jongsma ML, Zeerleder S, Spaapen RM, Wouters D. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research. J Immunol Methods 2018;456:15-22. [PMID: 29447841 DOI: 10.1016/j.jim.2018.02.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
10 Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, Takanami E, Meyer NC, Frees K, Thomas CP, Nester C, Smith RJH. Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29:2809-19. [PMID: 30377230 DOI: 10.1681/ASN.2018070759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
11 Wu X, Spitzer D, Mao D, Peng SL, Molina H, Atkinson JP. Membrane protein Crry maintains homeostasis of the complement system. J Immunol 2008;181:2732-40. [PMID: 18684964 DOI: 10.4049/jimmunol.181.4.2732] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
12 Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008;111:624-32. [PMID: 17914026 DOI: 10.1182/blood-2007-04-084533] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 6.8] [Reference Citation Analysis]
13 Antón J. Síndromes autoinflamatorios. Medicina Clínica 2011;136:3-9. [DOI: 10.1016/s0025-7753(11)70002-1] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]
14 Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods. 2011;365:8-26. [PMID: 21215749 DOI: 10.1016/j.jim.2010.12.020] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 9.8] [Reference Citation Analysis]
15 Martínez-Barricarte R, Heurich M, Valdes-Cañedo F, Vazquez-Martul E, Torreira E, Montes T, Tortajada A, Pinto S, Lopez-Trascasa M, Morgan BP, Llorca O, Harris CL, Rodríguez de Córdoba S. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010;120:3702-12. [PMID: 20852386 DOI: 10.1172/JCI43343] [Cited by in Crossref: 163] [Cited by in F6Publishing: 83] [Article Influence: 13.6] [Reference Citation Analysis]
16 Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:345-357. [PMID: 19625716 DOI: 10.1056/nejmoa0810739] [Cited by in Crossref: 368] [Cited by in F6Publishing: 153] [Article Influence: 28.3] [Reference Citation Analysis]
17 Liszewski MK, Fang CJ, Atkinson JP. Inhibiting complement activation on cells at the step of C3 cleavage. Vaccine 2008;26 Suppl 8:I22-7. [PMID: 19388160 DOI: 10.1016/j.vaccine.2008.11.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
18 Li B, Allendorf DJ, Hansen R, Marroquin J, Cramer DE, Harris CL, Yan J. Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res 2007;67:7421-30. [PMID: 17671212 DOI: 10.1158/0008-5472.CAN-07-1465] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
19 Kavanagh D, Goodship TH. Update on evaluating complement in hemolytic uremic syndrome. Curr Opin Nephrol Hypertens. 2007;16:565-571. [PMID: 18089972 DOI: 10.1097/mnh.0b013e3282f0872f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]